Related Experiment Videos
Pretargeting with the affinity enhancement system for radioimmunotherapy
J Barbet1, F Kraeber-Bodéré, J P Vuillez
1INSERM Research Unit 463, Nantes, France.
Cancer Biotherapy & Radiopharmaceuticals
|June 13, 2000
Summary
The Affinity Enhancement System (AES) uses antibodies and radiolabeled haptens for targeted cancer therapy. This pretargeting method shows promise for delivering high radiation doses to tumors with minimal normal tissue exposure.
Area of Science:
- Oncology
- Radiochemistry
- Immunotherapy
Background:
- Pretargeting strategies enhance the efficacy and specificity of radioimmunotherapy.
- The Affinity Enhancement System (AES) is a novel pretargeting technique.
Purpose of the Study:
- To evaluate the efficacy of the Affinity Enhancement System (AES) in delivering targeted radiation doses to tumor cells.
- To assess the safety and effectiveness of AES in clinical radioimmunotherapy.
Main Methods:
- Utilizing bispecific antibodies and radiolabeled bivalent haptens for cooperative binding to target cells in vivo.
- Administering the Affinity Enhancement System (AES) for radioimmunotherapy.
Main Results:
- AES demonstrated the ability to deliver high radiation doses to tumor cells.
- High tumor-to-normal tissue contrast ratios were achieved.
- Long activity residence times in tumors were observed.
- Preliminary clinical results for medullary thyroid carcinomas and lung cancers are promising.
Conclusions:
- The Affinity Enhancement System (AES) is an effective pretargeting technique for radioimmunotherapy.
- AES offers a promising approach for treating various cancers, including medullary thyroid carcinomas and lung cancers.